系统性淀粉样变性:识别、预后与治疗的系统综述
IMPORTANCE: Many patients with systemic amyloidosis are underdiagnosed. Overall, 25% of patients with immunoglobulin light chain (AL) amyloidosis die within 6 months of diagnosis and 25% of patients with amyloid transthyretin (ATTR) amyloidosis die within 24 months of diagnosis.…
要点
- 成人非糖尿病肾病综合征、射血分数保留心衰等需警惕淀粉样变性。
- 分期可仅通过血液检测完成。
- AL型治疗在高剂量化疗联合干细胞移植或硼替佐米方案间选择。
核心结论
- 所有类型的淀粉样变性均诊断不足,但现有获批疗法可改善生存或残疾与生活质量。
- 对累及心、肾、肝或神经系统的多系统疾病患者应考虑本病诊断。
研究设计与样本
- 由参考馆员进行2000年1月1日至2019年12月31日的全面文献检索。
- 纳入文献包括12项随机临床试验(共3074例患者)、9项病例系列和3项队列研究。
主要发现
- 变异型ATTR淀粉样变性估计发病率0.3例/百万人/年,患病率估计5.2例/百万人。
- 野生型ATTR估计患病率155至191例/百万人。
- 25%的AL淀粉样变性患者诊断后6个月内死亡,25%的ATTR淀粉样变性患者诊断后24个月内死亡。
关键数值与推荐
- 成人非糖尿病肾病综合征需考虑淀粉样变性鉴别诊断。
- 射血分数保留的心力衰竭(尤其伴限制性特征)需考虑本病。
- 不明原因肝肿大且影像学无异常、伴远端感觉症状(麻木、感觉异常、感觉迟钝)的周围神经病需考虑本病。
- 意义未明单克隆丙种球蛋白病伴非典型临床特征需考虑本病。
- AL淀粉样变性治疗选择包括高剂量化疗联合干细胞移植或基于硼替佐米的化疗;ATTR有3种FDA获批疗法,取决于临床表型。
临床怎么用
- 对多系统受累(心、肾、肝、神经)患者应警惕淀粉样变性并尽早诊断。
- 可仅通过血液检测进行分期,辅助预后判断与咨询。
- AL型根据风险选择高剂量化疗联合干细胞移植或硼替佐米方案。
- ATTR型根据临床表型选用FDA获批的3种疗法之一。
局限性
- 检索截止2019年12月31日,未纳入此后证据。
- 排除病例报告、非英语文献及少于10例的病例系列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Many patients with systemic amyloidosis are underdiagnosed. Overall, 25% of patients with immunoglobulin light chain (AL) amyloidosis die within 6 months of diagnosis and 25% of patients with amyloid transthyretin (ATTR) amyloidosis die within 24 months of diagnosis. Effective therapy exists but is ineffective if end-organ damage is severe. OBJECTIVE: To provide evidence-based recommendations that could allow clinicians to diagnose this rare set of diseases earlier and enable accurate staging and counseling about prognosis. EVIDENCE REVIEW: A comprehensive literature search was conducted by a reference librarian with publication dates from January 1, 2000, to December 31, 2019. Key search terms included amyloid, amyloidosis, nephrotic syndrome, heart failure preserved ejection fraction, and peripheral neuropathy. Exclusion criteria included case reports, non-English-language text, and case series of fewer than 10 patients. The authors independently selected and appraised relevant literature. FINDINGS: There was a total of 1769 studies in the final data set. Eighty-one articles were included in this review, of which 12 were randomized clinical trials of therapy that included 3074 patients, 9 were case series, and 3 were cohort studies. The incidence of AL amyloidosis is approximately 12 cases per million persons per year and there is an estimated prevalence of 30 000 to 45 000 cases in the US and European Union. The incidence of variant ATTR amyloidosis is estimated to be 0.3 cases per year per million persons with a prevalence estimate of 5.2 cases per million persons. Wild-type ATTR is estimated to have a prevalence of 155 to 191 cases per million persons. Amyloidosis should be considered in the differential diagnosis of adult nondiabetic nephrotic syndrome; heart failure with preserved ejection fraction, particularly if restrictive features are present; unexplained hepatomegaly without imaging abnormalities; peripheral neuropathy with distal sensory symptoms, such as numbness, paresthesia, and dysesthesias (although the autonomic manifestations occasionally may be the presenting feature); and monoclonal gammopathy of undetermined significance with atypical clinical features. Staging can be performed using blood testing only. Therapeutic decision-making for AL amyloidosis involves choosing between high-dose chemotherapy and stem cell transplant or bortezomib-based chemotherapy. There are 3 therapies approved by the US Food and Drug Administration for managing ATTR amyloidosis, depending on clinical phenotype. CONCLUSIONS AND RELEVANCE: All forms of amyloidosis are underdiagnosed. All forms now have approved therapies that have been demonstrated to improve either survival or disability and quality of life. The diagnosis should be considered in patients that have a multisystem disorder involving the heart, kidney, liver, or nervous system.
引用
- Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020. PMID: 32633805. doi:10.1001/jama.2020.5493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。